effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes

New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1  Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabetic kidney disease1Empagliflozin is not indicated for the prevention of kidney disease
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news